EUCTR2019-001279-34-IT进行中（未招募）1 期
A multicenter, open-label extension study to evaluate the long-term safety, tolerability and efficacy of orally administered GLPG1690 in subjects with systemic sclerosis -
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- GALAPAGOS NV
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Male or female subjects who completed the 24-week treatment period of Study GLPG1690-CL-204 and who according to the investigator’s judgment may benefit from long-term treatment with GLPG1690.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 27
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 3
排除标准
- •- Any condition or circumstances that, in the opinion of the investigator, may make a subject unlikely or unable to complete the study or comply with study procedures and requirements.
研究者
相似试验
进行中（未招募）
1 期
A clinical study to test long term safety of GLPG1690 for patients with systemic sclerosisSystemic sclerosisEUCTR2019-001279-34-DEGalapagos NV30
进行中（未招募）
1 期
A clinical study to test long term safety of GLPG1690 for patients with systemic sclerosisMedDRA version: 21.0Level: LLTClassification code 10042953Term: Systemic sclerosisSystem Organ Class: 100000004859Systemic sclerosisEUCTR2019-001279-34-GBGalapagos NV30
进行中（未招募）
1 期
A clinical study to test long term safety of GLPG1690 for patients with systemic sclerosisMedDRA version: 20.0Level: LLTClassification code 10042953Term: Systemic sclerosisSystem Organ Class: 100000004859Systemic sclerosisEUCTR2019-001279-34-ESGalapagos NV30
招募中
3 期
A Study to evaluate the safety and tolerability of dapirolizumab pegol in study participants with systemic lupus erythematosus.M320 Drug-induced systemic lupus erythematosusDrug-induced systemic lupus erythematosusM320PER-022-22CB Biopharma SR10
进行中（未招募）
不适用
An open-label, multi-centre, extension study evaluation the long-term safety and tolerability of Degarelix one-month depots in patients with prostate cancerMedDRA version: 7.0Level: pr tClassification code 10060862Prostate CancerEUCTR2004-003814-40-HUFerring Pharmaceuticals A/S130